Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 172

Results For "IDA"

1727 News Found

Bayer delivers robust performance despite pandemic
News | February 26, 2021

Bayer delivers robust performance despite pandemic

The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.


Unichem Laboratories receives ANDA approval for Apremilast Tablets
News | February 20, 2021

Unichem Laboratories receives ANDA approval for Apremilast Tablets

Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis .


Dr. Reddy's initiates process for emergency use authorization of Sputnik V
News | February 20, 2021

Dr. Reddy's initiates process for emergency use authorization of Sputnik V

Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.


Lupin launches posaconazole delayed-release tablets
News | February 18, 2021

Lupin launches posaconazole delayed-release tablets

posaconazole delayed-release tablets 100 mg are the generic equivalent of Noxafil.


Glenmark Q3 FY21 net profit up 30% at Rs 248 Cr
News | February 15, 2021

Glenmark Q3 FY21 net profit up 30% at Rs 248 Cr

The jump in profit is due to the better performance of the API business.


Jubilant Pharmova recovers: ICICI Securities
News | February 13, 2021

Jubilant Pharmova recovers: ICICI Securities

Jubilant announced the completion of demerger of pharma and LSI business into two separate companies


WACKER acquires plasmid DNA Manufacturer Genopis
News | February 05, 2021

WACKER acquires plasmid DNA Manufacturer Genopis

WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).


Laurus Q3 FY21 revenue up 76%; PAT grows 274%
News | January 29, 2021

Laurus Q3 FY21 revenue up 76%; PAT grows 274%

The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.


Lonza reports 12% sales growth in 2020
News | January 28, 2021

Lonza reports 12% sales growth in 2020

Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.


Slow recovery in biosimilars for Biocon: ICICI Securities
News | January 26, 2021

Slow recovery in biosimilars for Biocon: ICICI Securities

Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.